A Clinical Study on the Use of Methotrexate in Rheumatoid Arthritis Based on CDAI Score
Abstract
Methotrexate (MTX) has been used in the treatment of rheumatoid arthritis for more than 2 decades. It has proven its efficacy in the treatment of rheumatoid arthritis in numerous randomized controlled trials. Compared with other second-line drugs, a higher percentage of patients can continue therapy with MTX over a prolonged period. However, its long-term effectiveness in RA remains unclear. Therefore, a retrospective observational study was performed from the period of 2016-21.
Objectives: To evaluate the treatment plan and use of MTX in RA patients and to determine the efficacy of MTX therapy in Rheumatoid arthritis based on the CDAI score.
Methodology: A retrospective multicentric observational study was performed for 5 years on patients who were diagnosed with rheumatoid arthritis & were on methotrexate therapy. The statistical analysis was done using SPSS version 20.
Results and Discussion: A total of 763 patients were enrolled in the study, out of which 84.53% were females and 15.46% were males. Among the subjects, 11.8 % presented with low disease activity, 50.2 % presented with moderate disease activity, and 37.7% presented with high disease activity. 14.15% of patients were put on methotrexate monotherapy while the remaining 85.85% of patients were given MTX in combination with other synthetic DMARDs. Out of the total patients that were given combination therapy, 87.94% were on MTX+HCQ treatment.
Conclusion: Methotrexate has been proven to be efficacious in the treatment of the Rheumatoid Arthritis.
Keywords: Methotrexate, Rheumatoid Arthritis, CDAI Score
Keywords:
Methotrexate, Rheumatoid Arthritis, CDAI scoreDOI
https://doi.org/10.22270/jddt.v12i5-S.5737References
Barbara G. Wells, Joseph T. Dipiro, Terry L. Schwinghammer, Cecily V. Dipiro. Pharmacotherapy Handbook. 7th ed. The McGraw-Hill Companies: P. 31
Marie A. Chisholm-Burns, Barbara G. Wells, Terry L. Schwinghammer, Patrick M. Malone, Jill M. Kolesar, John C. Rotschafer, Joseph T. Dipiro. Pharmacotherapy: Principle and Practice. The McGraw-Hill Companies: P.867. Doi: 10.1036/0071448802
Cate Whittlesea, Karen Hodson. Clinical Pharmacy and Therapeutics. Elsevier: 6th ed, P. 923.
Stuart H Ralston, Lan D Penman, Mark WJ Strachan, Richard P Hobson. Davidson's Principles and Practice of Medicine. Elsevier. 23rd ed. Pg no: 65
Gaies E, Jebabli N, Trabelsi S, Salouage I, Charfi R, Lakhal M, Klouz A. Methotrexate side effects: review article. J Drug Metab Toxicol. 2012; 3(4):1-5. https://doi.org/10.4172/2157-7609.1000125
O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, Garwood V, Maloley P, Klassen LW, Wees S, Klein H. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. New England Journal of Medicine. 1996 May 16; 334(20):1287-91. https://doi.org/10.1056/NEJM199605163342002
Singer O, Gibofsky A. Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011. Current opinion in rheumatology. 2011 May 1; 23(3):288-92. https://doi.org/10.1097/BOR.0b013e328344f2e4
Katchamart W, Trudeau J, Phumethum V, Bombardier C. Methotrexate monotherapy versus methotrexate combination therapy with non‐biologic disease-modifying anti-rheumatic drugs for rheumatoid arthritis. Cochrane database of systematic reviews. 2010(4). https://doi.org/10.1002/14651858.CD008495
Schapink L, van den Ende CH, Gevers LA, van Ede AE, den Broeder AA. The effects of methotrexate and hydroxychloroquine combination therapy vs methotrexate monotherapy in early rheumatoid arthritis patients. Rheumatology. 2019 Jan 1; 58(1):131-4. https://doi.org/10.1093/rheumatology/key275
Published
Abstract Display: 536 
PDF Downloads: 508 PDF Downloads: 65 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.